Study Examines Incidence, Risk Factors for ICI-Related Pneumonitis in NSCLC

Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.

Related Keywords

,Pneumonitis ,Immune Related Adverse Events ,Anti Ctla 4 ,Disease Progression ,Immune Checkpoint Inhibitors ,